tcf

BML-284 (Wnt agonist 1) is a potent, selective and , cell-permeable Wnt signaling activator.

TA-02 is a p38 MAPK inhibitor with IC50 of 20 nM.TA-02 especially inhibits TGFBR-2.

BML-284 hydrochloride (Wnt agonist 1 HCL) is a potent, selective Wnt canonical signaling activator and tubulin polymerization inhibitor.

TCF199, a conformational stabilizer, facilitates the interaction between the 14-3-3ζ/E R α peptide and the 14-3-3ζ/Chibby peptide, thereby stabilizing the 14-3-3/TAZ peptide complex. The dissociation constant (Kd) of TCF199 with the 14-3-3/TAZ complex is 122 μM.

TCF4/β-catenin-IN-1 (Compound 8b) is an inhibitor of TCF4/β-catenin that induces apoptosis. This compound enhances the expression of p53, caspase-3, caspase-8, caspase-9, and Bax proteins, while reducing Bcl-2 protein levels. TCF4/β-catenin-IN-1 also inhibits CYP3A4, CYP1A2, and CYP2C19, demonstrating significant cytotoxic activity in cancer cells.

CCT 031374 hydrobromide is a TCF/β-catenin inhibitor with antitumor activities.

TC-F 2 is a FAAH inhibitor.

β-catenin-IN-2, a potent inhibitor of β-catenin, is suitable for use in colorectal cancer research.

tCFA15, a trimethyl cyclohexenonic long-chain fatty alcohol with a 15-carbon atom side chain, may regulate Notch signaling and promote neuronal differentiation.

WAY262611 is a Wnt/β-catenin agonist and an inhibitor of Dkk1. It increases bone formation rate with EC50 of 0.63 μM in TCF-luciferase assay.

Toxoflavin (Xanthothricin) is an antagonist of the transcription factor 4 (TCF4)/β-catenin complex and also inhibits KDM4A.

LF3 is a specific inhibitor of canonical Wnt signaling by disrupting the interaction between β-catenin and TCF4 (IC50 < 2 μM)

6-(N-Trifluoroacetyl)caproic acid NHS is a reagent used in biochemical reactions.

N,N,N',N'-Tetramethylchloroformamidinium hexafluorophosphate (TCFH) is a bioconjugation reagent utilized in the prodrug research of the anticancer drug thioTEPA.

Adavivint (SM04690) is a selective inhibitor of the typical Wnt signaling pathway. In SW480 cells, EC50=19.5 nM was measured using high-throughput TCF/LEF reporter gene experiments.

MTOB (α-keto-γ-Methylthiobutyric acid) is a substrate for c-terminal binding protein (CtBP) that interferes with the carcinogenic activity of CtBP in cell culture and mice. It also actively regulates TCF-4 signaling, leading to cancer stem cell (CSC) growth and self-renewal.

Hematein inhibits Akt/PKB Ser129 phosphorylation, the Wnt/TCF pathway, and increases apoptosis in lung cancer cells. Hematein is an oxidation product of hematoxylin acted as a dye and it also is an allosteric casein kinase II inhibitor (IC50: 0.74 μM).

CWP232228, a potent and selective Wnt / β-catenin signaling inhibitor, antagonizes the binding of β-catenin to T-cell factor (TCF) in the nucleus. CWP232228 inhibits the formation and metastasis of tumors by inhibiting the growth of breast cancer and live

FzM1.8 is an allosteric FZD4 agonist with a pEC50 of 6.4. FzM1.8 binds to FZD4, promotes TCF/LEF transcriptional activity in the absence of any WNT ligand, and activates the WNT/β-catenin pathway.

CCT070535 inhibits TCF-dependent transcription at the TCF level, displaying GI50 values of 17.6 μM in HT29 (APC mutation), 11.1 μM in HCT116 (oncogenic β-catenin), 11.8 μM in SW480 (APC mutation), and 13.4 μM in SNU475 (Axin mutation) cells.

BML-286 is a WNT pathway modulator with potential anticancer activity, inducing β-catenin- and TCF-dependent transcriptional activity, and can be used in the study of degenerative diseases, intestinal, breast, bladder, gastric, melanoma, leukemia, hepatocellular carcinoma and nephroblastoma.

I-67, a structural isomer of I-66, is a potent β-catenin inhibitor with an IC50 of less than 50 nM. It disrupts the interaction between β-catenin and T cell factor (TCF) transcription factors and exhibits anticancer properties.

BRD1172 (ML320) is a selective inhibitor of GSK3β, exhibiting an IC50 of 24 nM, demonstrating greater potency against GSK3β compared to CDK5. It significantly inhibits GSK3β-mediated Tau phosphorylation in SH-SY5Y cells and reduces the negative regulation by GSK3β on β-catenin degradation and TCF/LEF promoter activity. BRD1172 is applicable in research on Alzheimer's disease, cardiac hypertrophy, and cancer.

RMC-9945 (RM-044) is a KRAS inhibitor that is selective, covalent, and orally active against the RAS(ON) G12D mutation. It enhances the transcriptional activity of β-Catenin/TCF and demonstrates sustained disease control in early liver metastasis models of colorectal cancer.